vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Lifeway Foods, Inc. (LWAY). Click either name above to swap in a different company.
Lifeway Foods, Inc. is the larger business by last-quarter revenue ($55.4M vs $44.9M, roughly 1.2× AbCellera Biologics Inc.). Lifeway Foods, Inc. runs the higher net margin — 4.6% vs -19.9%, a 24.5% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 18.0%). Lifeway Foods, Inc. produced more free cash flow last quarter ($-17.4M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 11.4%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Lifeway Foods is an Illinois-based health food company founded in 1986. They are a leading U.S. supplier of kefir and fermented probiotic products to support the microbiome.
ABCL vs LWAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $55.4M |
| Net Profit | $-8.9M | $2.5M |
| Gross Margin | — | 27.8% |
| Operating Margin | -63.7% | 6.8% |
| Net Margin | -19.9% | 4.6% |
| Revenue YoY | 788.4% | 18.0% |
| Net Profit YoY | 73.9% | 1688.1% |
| EPS (diluted) | $-0.03 | $0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $55.4M | ||
| Q3 25 | $9.0M | $57.1M | ||
| Q2 25 | $17.1M | $53.9M | ||
| Q1 25 | $4.2M | $46.1M | ||
| Q4 24 | $5.0M | $46.9M | ||
| Q3 24 | $6.5M | $46.1M | ||
| Q2 24 | $7.3M | $49.2M | ||
| Q1 24 | $10.0M | $44.6M |
| Q4 25 | $-8.9M | $2.5M | ||
| Q3 25 | $-57.1M | $3.5M | ||
| Q2 25 | $-34.7M | $4.2M | ||
| Q1 25 | $-45.6M | $3.5M | ||
| Q4 24 | — | $-160.0K | ||
| Q3 24 | $-51.1M | $3.0M | ||
| Q2 24 | $-36.9M | $3.8M | ||
| Q1 24 | $-40.6M | $2.4M |
| Q4 25 | — | 27.8% | ||
| Q3 25 | — | 28.7% | ||
| Q2 25 | — | 28.6% | ||
| Q1 25 | — | 23.9% | ||
| Q4 24 | — | 25.3% | ||
| Q3 24 | — | 25.7% | ||
| Q2 24 | — | 27.0% | ||
| Q1 24 | — | 25.8% |
| Q4 25 | -63.7% | 6.8% | ||
| Q3 25 | -851.8% | 8.8% | ||
| Q2 25 | -290.2% | 10.8% | ||
| Q1 25 | -1479.6% | 3.4% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | -1439.4% | 9.1% | ||
| Q2 24 | -1276.2% | 11.0% | ||
| Q1 24 | -551.5% | 8.0% |
| Q4 25 | -19.9% | 4.6% | ||
| Q3 25 | -637.8% | 6.2% | ||
| Q2 25 | -203.3% | 7.9% | ||
| Q1 25 | -1077.2% | 7.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | -785.4% | 6.5% | ||
| Q2 24 | -504.3% | 7.7% | ||
| Q1 24 | -408.0% | 5.4% |
| Q4 25 | $-0.03 | $0.15 | ||
| Q3 25 | $-0.19 | $0.23 | ||
| Q2 25 | $-0.12 | $0.28 | ||
| Q1 25 | $-0.15 | $0.23 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | $-0.17 | $0.19 | ||
| Q2 24 | $-0.13 | $0.25 | ||
| Q1 24 | $-0.14 | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $5.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $85.8M |
| Total Assets | $1.4B | $105.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $5.6M | ||
| Q3 25 | $83.2M | $23.0M | ||
| Q2 25 | $92.4M | $21.2M | ||
| Q1 25 | $159.3M | $19.4M | ||
| Q4 24 | $156.3M | $16.7M | ||
| Q3 24 | $126.6M | $20.6M | ||
| Q2 24 | $148.3M | $14.6M | ||
| Q1 24 | $123.6M | $12.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.5M |
| Q4 25 | $966.9M | $85.8M | ||
| Q3 25 | $964.0M | $82.8M | ||
| Q2 25 | $1.0B | $78.7M | ||
| Q1 25 | $1.0B | $74.2M | ||
| Q4 24 | $1.1B | $71.9M | ||
| Q3 24 | $1.1B | $71.5M | ||
| Q2 24 | $1.1B | $68.0M | ||
| Q1 24 | $1.1B | $63.5M |
| Q4 25 | $1.4B | $105.6M | ||
| Q3 25 | $1.4B | $109.5M | ||
| Q2 25 | $1.4B | $98.3M | ||
| Q1 25 | $1.3B | $93.7M | ||
| Q4 24 | $1.4B | $90.5M | ||
| Q3 24 | $1.4B | $91.3M | ||
| Q2 24 | $1.4B | $84.9M | ||
| Q1 24 | $1.5B | $82.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $267.0K |
| Free Cash FlowOCF − Capex | $-44.6M | $-17.4M |
| FCF MarginFCF / Revenue | -99.4% | -31.5% |
| Capex IntensityCapex / Revenue | 21.9% | 31.9% |
| Cash ConversionOCF / Net Profit | — | 0.11× |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $-16.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $267.0K | ||
| Q3 25 | $-52.6M | $6.9M | ||
| Q2 25 | $-32.4M | $3.9M | ||
| Q1 25 | $-11.6M | $-150.0K | ||
| Q4 24 | $-108.6M | $-2.6M | ||
| Q3 24 | $-28.9M | $7.5M | ||
| Q2 24 | $-30.0M | $6.5M | ||
| Q1 24 | $-41.7M | $1.5M |
| Q4 25 | $-44.6M | $-17.4M | ||
| Q3 25 | $-61.5M | $1.8M | ||
| Q2 25 | $-45.8M | $1.6M | ||
| Q1 25 | $-22.2M | $-2.4M | ||
| Q4 24 | $-187.0M | $-3.8M | ||
| Q3 24 | $-47.4M | $5.9M | ||
| Q2 24 | $-50.1M | $5.1M | ||
| Q1 24 | $-65.8M | $-923.0K |
| Q4 25 | -99.4% | -31.5% | ||
| Q3 25 | -687.0% | 3.1% | ||
| Q2 25 | -267.9% | 3.0% | ||
| Q1 25 | -524.0% | -5.1% | ||
| Q4 24 | -3702.8% | -8.2% | ||
| Q3 24 | -728.4% | 12.8% | ||
| Q2 24 | -683.8% | 10.4% | ||
| Q1 24 | -661.5% | -2.1% |
| Q4 25 | 21.9% | 31.9% | ||
| Q3 25 | 99.7% | 9.0% | ||
| Q2 25 | 78.2% | 4.3% | ||
| Q1 25 | 251.1% | 4.8% | ||
| Q4 24 | 1552.7% | 2.7% | ||
| Q3 24 | 284.6% | 3.3% | ||
| Q2 24 | 274.6% | 2.9% | ||
| Q1 24 | 242.5% | 5.5% |
| Q4 25 | — | 0.11× | ||
| Q3 25 | — | 1.96× | ||
| Q2 25 | — | 0.92× | ||
| Q1 25 | — | -0.04× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.50× | ||
| Q2 24 | — | 1.73× | ||
| Q1 24 | — | 0.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
LWAY
| Drinkable Kefirotherthan Pro Bugs | $47.8M | 86% |
| Cheese | $4.7M | 8% |
| Cream And Other | $1.7M | 3% |
| Other | $1.2M | 2% |
